About
About Second Genome
Second Genome is a biopharmaceutical company with a mission to redefine disease in the context of microbiome medicine. We leverage our proprietary microbiome drug discovery and development platform to identify effective peptides, proteins and small molecule therapeutics that can address unmet medical needs. We are a tech-enabled biotech company that extracts microbial genetic insights to make transformational precision therapies and biomarkers.
Second Genome brings microbiome science to the discovery and development of therapeutic products. The company has established a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases. Second Genome’s development pipeline is fueled by novel technologies for identifying, screening and scientifically validating product candidates and microbial biomarkers. Second Genome’s technologies have been rigorously validated through partnerships with leading pharmaceutical and nutrition companies, as well as academic and governmental research institutions.
Transformative Collaborations
Collaborations are a critical way we leverage our microbiome platform and data science to advance understanding of and potential treatments for human diseases. We engage in strategic relationships focused in drug discovery, biomarkers and scientific research studies with industry leading biotechnology and pharmaceutical companies and academic institutions. We are continuously exploring strategic relationships related to our approach to microbiome science in our core disease focus areas, including oncology and gastro-intestinal diseases where microbiome science is most advanced. We are also interested in exploring opportunities related to metabolism and neurology. If you are interested in partnering with us, please reach out to us at [email protected].
Scientific Advisory Board
Our Scientific Advisory Board (SAB) comprises an accomplished group of scientific leaders who are experts in the fields of our targeted areas.
Prof. Reinhard Dummer, MD
Professor Reinhard Dummer is Professor of the University of Zurich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland and is a key thought leader in worldwide cutaneous oncology. Currently he is heading of the Skin Cancer Unit and the Clinical Trial Unit of the Department of Dermatology. Professor Dummer began his medical education in hematology and oncology before successfully completing his dermatology residency in Würzburg, Germany, and Zürich in 1992. He is Board Certified in allergology, clinical immunology, dermatology and dermatopathology.
Professor Dummer’s principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas. He has published more than 741 papers with a cumulative impact factor of more than 6372. He was past-president of the Melanoma Project Group of the Swiss Institute for Applied Cancer Research since 1999 -2016, is a member of German National Academy of Sciences (Leopoldina) and is past board member of the Society for Melanoma Research and past President of the International Society for Cutaneous Lymphomas. He is a founding and board member of the European Association of Dermato-Oncology (EADO), ESMO, URPP and past President of the European Society for Dermatological Research (ESDR).
In the last 20 years, he has developed a leading skin cancer center. This center offers best medical care, a network of clinical trials reaching from phase I to phase III. His contributions are acknowledge in many publications in outstanding journals such as New England Journal of Medicine, Lancet, Lancet Oncology, Press etc. Locally he is intensify cooperation with basic research group at the University and the federal University (ETH). This has resulted in translation work improving our understanding of cutaneous malignancies.